Product
CUDC-907
1 clinical trial
4 indications
Indication
lymphomaIndication
NeuroblastomaIndication
Brain TumorIndication
Solid TumorClinical trial
Phase 1 Trial of CUDC-907 in Children and Young Adults With Relapsed or Refractory Solid Tumors, CNS Tumors, or LymphomaStatus: Active (not recruiting), Estimated PCD: 2024-07-01